Claud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.
Claud Grigg, MD
Advertisement
Articles by Claud Grigg, MD
Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses the future treatment landscape of renal cell carcinoma (RCC).
Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses frontline tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC).
Advertisement
Latest Updated Articles
Dr. Grigg on Frontline Tyrosine Kinase Inhibitors in RCCPublished: October 23rd 2018 | Updated:
Dr. Grigg on the Future Treatment Landscape of Renal Cell CarcinomaPublished: October 30th 2018 | Updated:
Dr. Grigg Discusses CABOSUN Trial in mRCCPublished: February 12th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5